ТРУДНОСТИ ГИПОТЕНЗИВНОЙ ТЕРАПИИ: МЕСТО АНТАГОНИСТОВ КАЛЬЦИЯ
https://doi.org/10.15829/1560-4071-2013-2-65-68
Аннотация
Статья посвящена роли блокаторов кальциевых каналов в лечении артериальной гипертензии с наличием сопутствующей патологии. Уделяется внимание свежим данным исследований, в которых демонстрируется эффект этих препаратов на функцию почек, бронхов, на системное воспаление.
Отмечается, что подобные данные, выходящие за рамки “инструкции по применению” препаратов, необходимы врачу, чтобы выбрать оптимальную терапию для своего пациента.
Об авторах
Е. О. ТаратухинРоссия
к. м.н., кардиолог, ассистент кафедры
Н. В. Теплова
Россия
д. м.н., кардиолог, доцент кафедры
Список литературы
1. Armario P., Waeber B. Therapeutic strategies to improve control of hypertension. J Hypertens, 2013; Mar:31 Suppl1:9–12.
2. Hoyer J. Non-pharmacological and pharmacological treatment of arterial hypertension: current situation. Herz, 2012; 37 (7):728–34.
3. Rump L. C. Efficacy and tolerability of the fixed lercanidipine-enalapril combination in the treatment of patients with essential hypertension. Arzneimittelforschung, 2010; 60:24–30.
4. Yeh J. L., Hsu J. H., Liang J. C. et al. Lercanidipine and labedipinedilol-A attenuate lipopolysaccharide/interferon-gamma-induced inflammation in rat vascular smooth muscle cells. Atherosclerosis, 2013; 226 (2):364–72.
5. Cacciatore F., Bruzzese G., Vitale D. F. et al. Effects of ACE inhibition on circulating endothelial progenitor cells, vascular damage and oxidative stress in hypertensive patients. Eur J Clin Pharmacol. 2011; 67:877–93.
6. Farah R., Khamisy-Farah R., Shurtz-Swirski R. Calcium channel blocker effect on insulin resistance and inflammatory markers in essential hypertension patients. Int Angiol, 2013; 32:85–93.
7. Chalmers J., Arima H., Harrap S. et al. Global survey of current practice in management of hypertension as reported by societies affiliated with the international society of hypertension. J Hypertens, 2013; Feb 27.
8. Borghi C., Tartagni E. The older patient with hypertension: care and cure. Ther Adv Chronic Dis, 2012; 3 (5):231–6.
9. Manral S., Bhatia S., Sinha R. et al. Normalization of deranged signal transduction in lymphocytes of COPD patients by the novel calcium channel blocker H-DHPM. Biochimie, 2011; 93 (7):1146–56
10. Zhang J., Cao H., Zhang Y. et al. Nephroprotective effect of calcium channel blockers against toxicity of lead exposure in mice. Toxicol Lett, 2013; Feb 18.
11. Oguzhan N., Cilan H., Sipahioglu M. et al. The lack of benefit of a combination of an angiotensin receptro blocker and calcium channel blocker on contrast-induced nephropathy in patients with chronic kidney disease. Renal Failure, 2013; Feb 18.
12. Ott C., Schneider M. P., Raff U. et al. Effects of manidipine vs amlodipine on intrarenal haemodynamics in patients with arterial hypertension. Brit J Clin Pharmacol, 2013; 75 (1):129–35.
13. Alviar C. L., Devarapally S., Nadkarni G. N. et al. Efficacy and safety of dual calcium channel blockade for the treatment of hypertension: a meta-analysis. Am J Hypertens, 2013; 26 (2):287–97.
14. Duprez D. Treatment of isolated systolic hypertension in elderly. Expert Rev Cardiovasc Ther, 2012; 10 (11):1367–73.
15. Xu H., Zheng H., Shen Y. et al. Polymorphism of the methylene tetrahydrofolate reductase gene C677T and its influence on the antihypertensive and vascular protective effects of short-term lercanidipine treatment. Gene, 2012; 500: 207–10.
16. Sansanayudh N, Wongwiwatt S, Veerayuth S. Comparison of changes of body water measured by using bioelectrical impedance analysis between lercanidipine and amlodipine therapy in hypertensive outpatients. J Med Assoc Thai, 2010;93: 84–92.
17. Makarounas K., Glover S., Ferrari P. Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers. Clin Ther, 2009; 31 (8):1652–63.
Рецензия
Для цитирования:
Таратухин Е.О., Теплова Н.В. ТРУДНОСТИ ГИПОТЕНЗИВНОЙ ТЕРАПИИ: МЕСТО АНТАГОНИСТОВ КАЛЬЦИЯ. Российский кардиологический журнал. 2013;(2):65-68. https://doi.org/10.15829/1560-4071-2013-2-65-68
For citation:
Taratukhin E.O., Teplova N.V. Challenges in hypotensive therapy: the role of calcium antagonists. Russian Journal of Cardiology. 2013;(2):65-68. (In Russ.) https://doi.org/10.15829/1560-4071-2013-2-65-68